Wellness program for neuromyelitis optica patients
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial tests a structured wellness program to improve quality of life for people with neuromyelitis optica (NMOSD). It is designed to be accessible for any level of disability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of NMOSD (using 2015 guidelines).
- You must not have had a relapse in the last 30 days.
- You must be able to give your own consent and take part in the study.
- You cannot be taking part in another trial or wellness program right now.
- If you start certain medications (like stimulants or dalfampridine) between signing up and starting the study, you won't be able to join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a low dose of a protein called IL-2 can safely help control the immune system in people with neuromyelitis optica spectrum disorder (NMOSD). It aims to reduce disease activity and improve symptoms.
This is a registry that collects health information from adults with neuromyelitis optica spectrum disorder (NMOSD). It aims to better understand NMOSD and support future research, including studies of emerging therapies.
This trial tests a new antibody-based medicine to help people recover from an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the eyes and spinal cord. If you are having a recent flare-up and are already getting or planning to get steroid treatment, this study might offer an additional option to reduce damage and speed recovery.
This trial tests a new stem cell treatment for people with a severe relapse of neuromyelitis optica (NMO), a rare autoimmune disease that affects the eyes and spinal cord. The treatment may help reduce damage and improve recovery.
This trial tests a music-based walking therapy (called MR-C-014) to see if it is safe and well-tolerated for people with NMOSD who have trouble walking. It may help improve your walking pattern and strength.
This study uses MRI scans to look for hidden disease activity in people with NMOSD who feel stable and are already on rituximab. The goal is to catch any signs of damage early, which might help prevent future disability.
Hear when a new Neuromyelitis Optica Spectrum Disorder (NMOSD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.